

**Supplementary Table 1.** Demographics and baseline characteristics in subjects that completed the 12-month follow-up.

	<b>Overall (n=15)</b>	<b>Group 1 (n=9)</b>	<b>Group 2 (n=6)</b>
<b>Age, Mean (SD), y</b>	51.9 (12.2)	52.3 (10.8)	51.4 (15.1)
<b>Female, %</b>	27	22	33
<b>Time since amputation, Mean (SD), y</b>	7.8 (7.8)	6.8 (5.3)	9.4 (11.0)
<b>Time since onset of RLP, Mean (SD), y</b>	7.8 (8.0)	6.4 (5.4)	9.8 (10.8)
<b>Time since onset of PLP, Mean (SD), y</b>	8.0 (7.7)	6.8 (5.3)	9.8 (10.8)
<b>Level of Amputation</b>			
Above knee, n (%)	9 (60)	8 (89)	1 (17)
Below knee, n (%)	6 (40)	1 (11)	5 (83)
<b>Treatment History (% Currently in use, % Previously in use)</b>			
Opioid medication	40, 53	22, 78	17, 67
Non-opioid medications	67, 13	67, 11	67, 17
Surface stimulation	0, 27	0, 22	0, 33
Spinal cord stimulation	0, 0	0, 0	0, 0
Physical therapy	7, 80	11, 67	0, 100
Acupuncture	0, 7	0, 11	0, 0
Steroid injection	0, 13	0, 11	0, 17
Botulinum toxin injection	0, 0	0, 0	0, 0
Nerve block	0, 27	0, 0	0, 67
Other	0, 0	0, 0	0, 0